Real world pharmacovigilance assessment of drug related macular degeneration risks
Abstract Macular degeneration is a leading cause of irreversible vision loss, significantly impacting quality of life. To enhance clinical practice and reduce the risk of drug-related macular degeneration, we analyzed drug-related trends using real-world data. Disproportionality analysis of adverse...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-84679-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841544620413026304 |
|---|---|
| author | Xiaodong Chen Shinan Wu Shaopan Wang Chaofeng Yu Zihan Guo Shiya Huang Peixin Cai Yanliang Miao Shiying Li Qian Chen |
| author_facet | Xiaodong Chen Shinan Wu Shaopan Wang Chaofeng Yu Zihan Guo Shiya Huang Peixin Cai Yanliang Miao Shiying Li Qian Chen |
| author_sort | Xiaodong Chen |
| collection | DOAJ |
| description | Abstract Macular degeneration is a leading cause of irreversible vision loss, significantly impacting quality of life. To enhance clinical practice and reduce the risk of drug-related macular degeneration, we analyzed drug-related trends using real-world data. Disproportionality analysis of adverse event reports from the FDA Adverse Event Reporting System (FAERS, 2004–2023) identified 67,683 cases involving 1402 drugs. Among these, 42 drugs were linked to significant risks, including treatments for breast cancer (tamoxifen, raloxifene, anastrozole, letrozole) and diabetes (insulin lispro, insulin human). The BCPNN algorithm revealed that 45.2% (19/42) of these drugs had the strongest associations with macular degeneration, with pentosan polysulfate sodium, travoprost, and tolterodine being the highest-risk drugs. Lifitegrast, nicotine, and travoprost were associated with the shortest onset times for ocular adverse events. Among drug classes, glucocorticosteroids were linked to the most rapid onset of ocular side effects (P < 0.001), typically occurring within two months compared to other drugs. Drug-related macular degeneration was more common in women (70.4%) and predominantly affected those aged 60–80. The incidence of drug-related macular degeneration has steadily increased in recent years. This study offers valuable pharmacovigilance insights, highlighting drugs and demographic factors linked to macular degeneration. |
| format | Article |
| id | doaj-art-c328781b2b0f4a759f62fd9685cc7e0c |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-c328781b2b0f4a759f62fd9685cc7e0c2025-01-12T12:24:28ZengNature PortfolioScientific Reports2045-23222025-01-0115111610.1038/s41598-024-84679-4Real world pharmacovigilance assessment of drug related macular degeneration risksXiaodong Chen0Shinan Wu1Shaopan Wang2Chaofeng Yu3Zihan Guo4Shiya Huang5Peixin Cai6Yanliang Miao7Shiying Li8Qian Chen9Xiamen University Affiliated Xiamen Eye Center, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Fujian Engineering and Research Center of Eye Regenerative Medicine, Eye Institute of Xiamen University, School of Medicine, Xiamen UniversityXiamen University Affiliated Xiamen Eye Center, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Fujian Engineering and Research Center of Eye Regenerative Medicine, Eye Institute of Xiamen University, School of Medicine, Xiamen UniversityXiamen University Affiliated Xiamen Eye Center, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Fujian Engineering and Research Center of Eye Regenerative Medicine, Eye Institute of Xiamen University, School of Medicine, Xiamen UniversityXiamen University Affiliated Xiamen Eye Center, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Fujian Engineering and Research Center of Eye Regenerative Medicine, Eye Institute of Xiamen University, School of Medicine, Xiamen UniversityXiamen University Affiliated Xiamen Eye Center, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Fujian Engineering and Research Center of Eye Regenerative Medicine, Eye Institute of Xiamen University, School of Medicine, Xiamen UniversityXiamen University Affiliated Xiamen Eye Center, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Fujian Engineering and Research Center of Eye Regenerative Medicine, Eye Institute of Xiamen University, School of Medicine, Xiamen UniversityXiamen University Affiliated Xiamen Eye Center, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Fujian Engineering and Research Center of Eye Regenerative Medicine, Eye Institute of Xiamen University, School of Medicine, Xiamen UniversityXiamen University Affiliated Xiamen Eye Center, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Fujian Engineering and Research Center of Eye Regenerative Medicine, Eye Institute of Xiamen University, School of Medicine, Xiamen UniversityDepartment of Ophthalmology, The First Affiliated Hospital of Xiamen UniversityXiamen University Affiliated Xiamen Eye Center, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Fujian Engineering and Research Center of Eye Regenerative Medicine, Eye Institute of Xiamen University, School of Medicine, Xiamen UniversityAbstract Macular degeneration is a leading cause of irreversible vision loss, significantly impacting quality of life. To enhance clinical practice and reduce the risk of drug-related macular degeneration, we analyzed drug-related trends using real-world data. Disproportionality analysis of adverse event reports from the FDA Adverse Event Reporting System (FAERS, 2004–2023) identified 67,683 cases involving 1402 drugs. Among these, 42 drugs were linked to significant risks, including treatments for breast cancer (tamoxifen, raloxifene, anastrozole, letrozole) and diabetes (insulin lispro, insulin human). The BCPNN algorithm revealed that 45.2% (19/42) of these drugs had the strongest associations with macular degeneration, with pentosan polysulfate sodium, travoprost, and tolterodine being the highest-risk drugs. Lifitegrast, nicotine, and travoprost were associated with the shortest onset times for ocular adverse events. Among drug classes, glucocorticosteroids were linked to the most rapid onset of ocular side effects (P < 0.001), typically occurring within two months compared to other drugs. Drug-related macular degeneration was more common in women (70.4%) and predominantly affected those aged 60–80. The incidence of drug-related macular degeneration has steadily increased in recent years. This study offers valuable pharmacovigilance insights, highlighting drugs and demographic factors linked to macular degeneration.https://doi.org/10.1038/s41598-024-84679-4FAERSDisproportionality analysisDrug-related macular degenerationMedicationPharmacovigilance |
| spellingShingle | Xiaodong Chen Shinan Wu Shaopan Wang Chaofeng Yu Zihan Guo Shiya Huang Peixin Cai Yanliang Miao Shiying Li Qian Chen Real world pharmacovigilance assessment of drug related macular degeneration risks Scientific Reports FAERS Disproportionality analysis Drug-related macular degeneration Medication Pharmacovigilance |
| title | Real world pharmacovigilance assessment of drug related macular degeneration risks |
| title_full | Real world pharmacovigilance assessment of drug related macular degeneration risks |
| title_fullStr | Real world pharmacovigilance assessment of drug related macular degeneration risks |
| title_full_unstemmed | Real world pharmacovigilance assessment of drug related macular degeneration risks |
| title_short | Real world pharmacovigilance assessment of drug related macular degeneration risks |
| title_sort | real world pharmacovigilance assessment of drug related macular degeneration risks |
| topic | FAERS Disproportionality analysis Drug-related macular degeneration Medication Pharmacovigilance |
| url | https://doi.org/10.1038/s41598-024-84679-4 |
| work_keys_str_mv | AT xiaodongchen realworldpharmacovigilanceassessmentofdrugrelatedmaculardegenerationrisks AT shinanwu realworldpharmacovigilanceassessmentofdrugrelatedmaculardegenerationrisks AT shaopanwang realworldpharmacovigilanceassessmentofdrugrelatedmaculardegenerationrisks AT chaofengyu realworldpharmacovigilanceassessmentofdrugrelatedmaculardegenerationrisks AT zihanguo realworldpharmacovigilanceassessmentofdrugrelatedmaculardegenerationrisks AT shiyahuang realworldpharmacovigilanceassessmentofdrugrelatedmaculardegenerationrisks AT peixincai realworldpharmacovigilanceassessmentofdrugrelatedmaculardegenerationrisks AT yanliangmiao realworldpharmacovigilanceassessmentofdrugrelatedmaculardegenerationrisks AT shiyingli realworldpharmacovigilanceassessmentofdrugrelatedmaculardegenerationrisks AT qianchen realworldpharmacovigilanceassessmentofdrugrelatedmaculardegenerationrisks |